Pharmacogenomics and pharmacokinetics study of drug metabolizing enzyme in patients with severe adverse drug reaction due to anti-neoplastics

Pharmacogenomics and pharmacokinetics study of drug metabolizing enzyme in patients with severe adverse drug reaction due to anti-neoplastics - Pharmacogenomics and pharmacokinetics in patients with severe adverse drug reaction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002339

Enrollment

Registered

2009-08-14

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unpredictable severe adverse drug reaction including death due to anti-neoplastics

Exclusion criteria

Exclusion criteria: Informed consent not obtained

Design outcomes

Primary

Measure	Time frame
Genetic polymorphism drug or metabolite concentration	—

Countries

Japan

Contacts

Public ContactHiroshi Ishiguro

Graduate Schhol of Medicine Kyoto University Department of Target Therapy Oncology

hkkishi@kuhp.kyoto-u.ac.jp075-751-4950

Outcome results